{"nctId":"NCT01717638","briefTitle":"Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1","startDateStruct":{"date":"2012-11"},"conditions":["Meningococcal Disease","Meningococcal Meningitis"],"count":805,"armGroups":[{"label":"B+R246_12_48","type":"EXPERIMENTAL","interventionNames":["Biological: 1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine"]},{"label":"B+R246_18_48","type":"EXPERIMENTAL","interventionNames":["Biological: 1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine"]},{"label":"B+R246_24_48","type":"EXPERIMENTAL","interventionNames":["Biological: 1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine"]},{"label":"B246_12_48","type":"EXPERIMENTAL","interventionNames":["Biological: 1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine"]},{"label":"B246_18_48","type":"EXPERIMENTAL","interventionNames":["Biological: 1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine"]},{"label":"B246_24_48","type":"EXPERIMENTAL","interventionNames":["Biological: 1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine"]},{"label":"B+R234_12_48","type":"EXPERIMENTAL","interventionNames":["Biological: 1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine"]},{"label":"B+R234_18_48","type":"EXPERIMENTAL","interventionNames":["Biological: 1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine"]},{"label":"B+R234_24_48","type":"EXPERIMENTAL","interventionNames":["Biological: 1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine"]},{"label":"B12 14_48","type":"EXPERIMENTAL","interventionNames":["Biological: 1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine"]},{"label":"B18 20_48","type":"EXPERIMENTAL","interventionNames":["Biological: 1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine"]},{"label":"B24 26_48","type":"EXPERIMENTAL","interventionNames":["Biological: 1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine"]},{"label":"B48_50","type":"EXPERIMENTAL","interventionNames":["Biological: 2 doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine"]}],"interventions":[{"name":"1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine","otherNames":["rMenB+OMV NZ"]},{"name":"2 doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine","otherNames":["rMenB+OMV NZ"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nA. Inclusion Criteria for naïve subjects, newly enrolled (B48\\_50):\n\n1. 4 years old (48 to 60 months) healthy male and female subjects will be recruited from the same sites as in study V72P12E1. The age window is defined as the first day the subject turns 4 years old up to the day before the subject turns 5 years old.\n2. For whom parent/legal guardian(s) has given written informed consent after the nature of the study has been explained.\n3. For whom parent/legal guardian(s) confirmed availability for the visit(s) scheduled in the study.\n4. In good health as determined by medical history, physical examination, clinical judgment of the investigator.\n\nB. Inclusion Criteria for follow-on participants (Groups B+R246 12\\_48, B+R246 18\\_48, B+R246 24\\_48, B246 12\\_48, B246 18\\_48, B246 24\\_48, B+R234 12\\_48, B+R234 18\\_48, B+R234 24\\_48, B12 14\\_48, B18 20\\_48, B24 26\\_48):\n\nInclusion criteria are the same as for Group B48\\_50, with the addition that they are subjects who completed the vaccination course of V72P12E1 study.\n\nExclusion Criteria:\n\nA. Exclusion Criteria for naïve subjects, newly enrolled (Group 7):\n\n1. Subjects whose parents/legal guardians are unwilling or unable to give written informed consent to participate in the study.\n2. History of any meningococcal B vaccine administration.\n3. Previous ascertained or suspected disease caused by N. meningitidis.\n4. Household contact with and/or intimate exposure to an individual with laboratory confirmed N. meningitidis.\n5. History of allergic reaction to any vaccine component.\n6. Significant chronic infection.\n7. Any serious chronic or progressive disease according to the judgment of the investigator (e.g., neoplasm, diabetes mellitus Type I, cardiac disease, hepatic disease, progressive neurological disease or seizure, either associated with fever or as part of an underlying neurological disorder or syndrome, autoimmune disease, HIV infection or AIDS, or blood dyscrasias or diathesis, signs of cardiac or renal failure or severe malnutrition).\n8. Known or suspected impairment/alteration of the immune system resulting from (for example) receipt of chronic immunosuppressive therapy or immunostimulants.\n9. Participation in another clinical trial within 90 days prior to enrolment or planned for during study.\n10. Family members and household members of research staff.\n11. Any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives.\n\nB. Exclusion Criteria for follow-on participants ((Groups B+R246 12\\_48, B+R246 18\\_48, B+R246 24\\_48, B246 12\\_48, B246 18\\_48, B246 24\\_48, B+R234 12\\_48, B+R234 18\\_48, B+R234 24\\_48, B12 14\\_48, B18 20\\_48, B24 26\\_48):\n\nExclusion criteria are the same as for Group B48\\_50, with the exception of criterion 2 and excluding participation in V72P12E1 for criterion 9.","healthyVolunteers":true,"sex":"ALL","minimumAge":"48 Months","maximumAge":"60 Months","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentages of Subjects With Persisting Serum Bactericidal Titers ≥1:5 and ≥1:8 (at 4 Years of Age), Who Had Previously Received Three Primary Doses and One Booster Dose of rMenB+OMV NZ Vaccine According to Different Schedules","description":"The antibody persistence at 4 years of age in children who had previously received 3 primary doses (at 2, 3, 4, or 2, 4, 6 months) followed by a booster dose (at 12,18 or 24 months) of rMenB+OMV NZ vaccine according to different schedules is compared with the response in naïve children and reported as percentages of subjects with human serum bactericidal assay (hSBA) titers ≥1:5 and ≥1:8.\n\nThe functional bactericidal antibodies directed against serogroup B meningococci were assessed using the Serum Bactericidal Assay (SBA) using human serum as the source of exogenous complement (hSBA).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"24","spread":null},{"groupId":"OG003","value":"20","spread":null},{"groupId":"OG004","value":"27","spread":null},{"groupId":"OG005","value":"35","spread":null},{"groupId":"OG006","value":"12","spread":null},{"groupId":"OG007","value":"25","spread":null},{"groupId":"OG008","value":"21","spread":null},{"groupId":"OG009","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"98","spread":null},{"groupId":"OG002","value":"97","spread":null},{"groupId":"OG003","value":"97","spread":null},{"groupId":"OG004","value":"100","spread":null},{"groupId":"OG005","value":"100","spread":null},{"groupId":"OG006","value":"90","spread":null},{"groupId":"OG007","value":"89","spread":null},{"groupId":"OG008","value":"96","spread":null},{"groupId":"OG009","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"12","spread":null},{"groupId":"OG003","value":"9","spread":null},{"groupId":"OG004","value":"11","spread":null},{"groupId":"OG005","value":"9","spread":null},{"groupId":"OG006","value":"10","spread":null},{"groupId":"OG007","value":"11","spread":null},{"groupId":"OG008","value":"11","spread":null},{"groupId":"OG009","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"68","spread":null},{"groupId":"OG002","value":"74","spread":null},{"groupId":"OG003","value":"55","spread":null},{"groupId":"OG004","value":"53","spread":null},{"groupId":"OG005","value":"80","spread":null},{"groupId":"OG006","value":"68","spread":null},{"groupId":"OG007","value":"75","spread":null},{"groupId":"OG008","value":"75","spread":null},{"groupId":"OG009","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"17","spread":null},{"groupId":"OG003","value":"11","spread":null},{"groupId":"OG004","value":"24","spread":null},{"groupId":"OG005","value":"28","spread":null},{"groupId":"OG006","value":"7","spread":null},{"groupId":"OG007","value":"21","spread":null},{"groupId":"OG008","value":"21","spread":null},{"groupId":"OG009","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"97","spread":null},{"groupId":"OG002","value":"93","spread":null},{"groupId":"OG003","value":"94","spread":null},{"groupId":"OG004","value":"94","spread":null},{"groupId":"OG005","value":"100","spread":null},{"groupId":"OG006","value":"90","spread":null},{"groupId":"OG007","value":"86","spread":null},{"groupId":"OG008","value":"96","spread":null},{"groupId":"OG009","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"8","spread":null},{"groupId":"OG003","value":"8","spread":null},{"groupId":"OG004","value":"3","spread":null},{"groupId":"OG005","value":"4","spread":null},{"groupId":"OG006","value":"2","spread":null},{"groupId":"OG007","value":"7","spread":null},{"groupId":"OG008","value":"11","spread":null},{"groupId":"OG009","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"53","spread":null},{"groupId":"OG002","value":"60","spread":null},{"groupId":"OG003","value":"48","spread":null},{"groupId":"OG004","value":"45","spread":null},{"groupId":"OG005","value":"65","spread":null},{"groupId":"OG006","value":"60","spread":null},{"groupId":"OG007","value":"61","spread":null},{"groupId":"OG008","value":"61","spread":null},{"groupId":"OG009","value":"56","spread":null}]}]}]},{"type":"PRIMARY","title":"Persisting Antibody Titers in Children (at 4 Years of Age) Who Had Previously Received Three Primary Doses and One Booster Dose of rMenB+OMV NZ Vaccine According to Different Schedules","description":"The persisting antibody titers at 4 years of age in children who had previously received 3 primary doses (at 2, 3, 4, or 2, 4, 6 months) followed by a booster dose (at 12, 18 or 24 months) of rMenB+OMV NZ vaccine according to different schedules is compared with the titers in naive children and reported as geometric mean titers (GMTs).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.75","spread":null},{"groupId":"OG001","value":"1.68","spread":null},{"groupId":"OG002","value":"2.41","spread":null},{"groupId":"OG003","value":"1.72","spread":null},{"groupId":"OG004","value":"1.99","spread":null},{"groupId":"OG005","value":"2.69","spread":null},{"groupId":"OG006","value":"1.51","spread":null},{"groupId":"OG007","value":"2.2","spread":null},{"groupId":"OG008","value":"2.2","spread":null},{"groupId":"OG009","value":"1.04","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"69","spread":null},{"groupId":"OG002","value":"69","spread":null},{"groupId":"OG003","value":"59","spread":null},{"groupId":"OG004","value":"57","spread":null},{"groupId":"OG005","value":"111","spread":null},{"groupId":"OG006","value":"52","spread":null},{"groupId":"OG007","value":"62","spread":null},{"groupId":"OG008","value":"101","spread":null},{"groupId":"OG009","value":"1.15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.25","spread":null},{"groupId":"OG001","value":"1.29","spread":null},{"groupId":"OG002","value":"1.38","spread":null},{"groupId":"OG003","value":"1.48","spread":null},{"groupId":"OG004","value":"1.34","spread":null},{"groupId":"OG005","value":"1.52","spread":null},{"groupId":"OG006","value":"1.32","spread":null},{"groupId":"OG007","value":"1.25","spread":null},{"groupId":"OG008","value":"1.62","spread":null},{"groupId":"OG009","value":"1.01","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.14","spread":null},{"groupId":"OG001","value":"7.36","spread":null},{"groupId":"OG002","value":"9.08","spread":null},{"groupId":"OG003","value":"7.86","spread":null},{"groupId":"OG004","value":"7.77","spread":null},{"groupId":"OG005","value":"15","spread":null},{"groupId":"OG006","value":"9.61","spread":null},{"groupId":"OG007","value":"11","spread":null},{"groupId":"OG008","value":"11","spread":null},{"groupId":"OG009","value":"8.75","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Ratios (GMRs) in Children (at 4 Years of Age) Who Had Previously Received Three Primary Doses and One Booster Dose of rMenB+OMV NZ Vaccine According to Different Schedules","description":"The GMRs of GMTs (48 months/one month post booster vaccination) at 4 years of age in children who had previously received 3 primary doses (at 2, 3, 4, or 2, 4, 6 months) followed by a booster dose (at 12,18 or 24 months) of rMenB+OMV NZ vaccine according to different schedules is reported.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.012","spread":null},{"groupId":"OG001","value":"0.013","spread":null},{"groupId":"OG002","value":"0.023","spread":null},{"groupId":"OG003","value":"0.0092","spread":null},{"groupId":"OG004","value":"0.013","spread":null},{"groupId":"OG005","value":"0.023","spread":null},{"groupId":"OG006","value":"0.0091","spread":null},{"groupId":"OG007","value":"0.023","spread":null},{"groupId":"OG008","value":"0.023","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.029","spread":null},{"groupId":"OG001","value":"0.032","spread":null},{"groupId":"OG002","value":"0.043","spread":null},{"groupId":"OG003","value":"0.031","spread":null},{"groupId":"OG004","value":"0.034","spread":null},{"groupId":"OG005","value":"0.054","spread":null},{"groupId":"OG006","value":"0.035","spread":null},{"groupId":"OG007","value":"0.037","spread":null},{"groupId":"OG008","value":"0.055","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.028","spread":null},{"groupId":"OG001","value":"0.094","spread":null},{"groupId":"OG002","value":"0.071","spread":null},{"groupId":"OG003","value":"0.043","spread":null},{"groupId":"OG004","value":"0.081","spread":null},{"groupId":"OG005","value":"0.11","spread":null},{"groupId":"OG006","value":"0.03","spread":null},{"groupId":"OG007","value":"0.082","spread":null},{"groupId":"OG008","value":"0.066","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"NA","spread":null},{"groupId":"OG003","value":"NA","spread":null},{"groupId":"OG004","value":"NA","spread":null},{"groupId":"OG005","value":"NA","spread":null},{"groupId":"OG006","value":"0.67","spread":null},{"groupId":"OG007","value":"0.91","spread":null},{"groupId":"OG008","value":"0.47","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentages of Subjects With Persisting Serum Bactericidal Titers ≥1:5 and ≥1:8 (at 4 Years of Age), Who Had Previously Received Two Catch up Doses of rMenB+OMV NZ Vaccine According to Different Schedules","description":"The antibody persistence in children at 4 year of age, who had previously received 2 catch up doses (at 12, 14 or 18, 20 or 24, 26 months) according to different schedules is reported as percentages of subjects with hSBA titers ≥1:5 and hSBA titers ≥1:8.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"9","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"60","spread":null},{"groupId":"OG002","value":"60","spread":null},{"groupId":"OG003","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"40","spread":null},{"groupId":"OG002","value":"60","spread":null},{"groupId":"OG003","value":"56","spread":null}]}]}]},{"type":"SECONDARY","title":"Persisting Antibody Titers in Children (at 4 Years of Age) Who Had Previously Received Two Catch up Doses of rMenB+OMV NZ Vaccine According to Different Schedules","description":"The persisting GMTs in children at 4 years of age, who had previously received 2 catch up doses (at 12, 14 or 18, 20 or 24, 26 months) of rMenB+OMV NZ vaccine according to different schedules are reported.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.61","spread":null},{"groupId":"OG001","value":"2.03","spread":null},{"groupId":"OG002","value":"1.69","spread":null},{"groupId":"OG003","value":"1.04","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"47","spread":null},{"groupId":"OG002","value":"69","spread":null},{"groupId":"OG003","value":"1.15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.15","spread":null},{"groupId":"OG001","value":"2.68","spread":null},{"groupId":"OG002","value":"1.06","spread":null},{"groupId":"OG003","value":"1.01","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.83","spread":null},{"groupId":"OG001","value":"9.67","spread":null},{"groupId":"OG002","value":"8.4","spread":null},{"groupId":"OG003","value":"8.75","spread":null}]}]}]},{"type":"SECONDARY","title":"GMRs of GMTs in Children (at 4 Years of Age) Who Had Previously Received Two Catch up Doses of rMenB+OMV NZ Vaccine According to Different Schedules","description":"The GMRs of GMTs (48 months/one month post last vaccination) in children at 4 years of age who had previously received 2 catch up doses (at 12, 14 or 18, 20 or 24, 26 months) of rMenB+OMV NZ vaccine according to different schedules.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.092","spread":null},{"groupId":"OG001","value":"0.18","spread":null},{"groupId":"OG002","value":"0.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.45","spread":null},{"groupId":"OG001","value":"1.9","spread":null},{"groupId":"OG002","value":"1.36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.28","spread":null},{"groupId":"OG001","value":"0.73","spread":null},{"groupId":"OG002","value":"0.42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"6.05","spread":null},{"groupId":"OG002","value":"6.88","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentages of Subjects With Serum Bactericidal Titers ≥1:5 and ≥1:8 After a 5th Dose of rMenB+OMV NZ Vaccine (at 4 Years of Age) Who Had Previously Received 3 Primary Doses and a Booster Dose of the Same Vaccine According to Different Schedules","description":"The Percentages of subjects with hSBA titers ≥1:5 and ≥1:8, one month after a 5th dose of rMenB+OMV NZ vaccine was given children who had previously received 3 primary doses (at 2, 3, 4,or 2, 4, 6 months) and a booster dose (at 12, 18 or 24 months) of the same vaccine according to different schedules is compared with the hSBA response of children who received first dose of rMenB+OMV NZ at 4 years of age.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"100","spread":null},{"groupId":"OG004","value":"100","spread":null},{"groupId":"OG005","value":"100","spread":null},{"groupId":"OG006","value":"97","spread":null},{"groupId":"OG007","value":"100","spread":null},{"groupId":"OG008","value":"100","spread":null},{"groupId":"OG009","value":"71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"100","spread":null},{"groupId":"OG004","value":"100","spread":null},{"groupId":"OG005","value":"100","spread":null},{"groupId":"OG006","value":"100","spread":null},{"groupId":"OG007","value":"100","spread":null},{"groupId":"OG008","value":"100","spread":null},{"groupId":"OG009","value":"90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"83","spread":null},{"groupId":"OG002","value":"94","spread":null},{"groupId":"OG003","value":"81","spread":null},{"groupId":"OG004","value":"88","spread":null},{"groupId":"OG005","value":"80","spread":null},{"groupId":"OG006","value":"95","spread":null},{"groupId":"OG007","value":"92","spread":null},{"groupId":"OG008","value":"92","spread":null},{"groupId":"OG009","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"89","spread":null},{"groupId":"OG002","value":"88","spread":null},{"groupId":"OG003","value":"93","spread":null},{"groupId":"OG004","value":"96","spread":null},{"groupId":"OG005","value":"93","spread":null},{"groupId":"OG006","value":"97","spread":null},{"groupId":"OG007","value":"100","spread":null},{"groupId":"OG008","value":"100","spread":null},{"groupId":"OG009","value":"77","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"100","spread":null},{"groupId":"OG004","value":"96","spread":null},{"groupId":"OG005","value":"100","spread":null},{"groupId":"OG006","value":"97","spread":null},{"groupId":"OG007","value":"100","spread":null},{"groupId":"OG008","value":"96","spread":null},{"groupId":"OG009","value":"63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"100","spread":null},{"groupId":"OG004","value":"100","spread":null},{"groupId":"OG005","value":"100","spread":null},{"groupId":"OG006","value":"100","spread":null},{"groupId":"OG007","value":"100","spread":null},{"groupId":"OG008","value":"100","spread":null},{"groupId":"OG009","value":"87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85","spread":null},{"groupId":"OG001","value":"61","spread":null},{"groupId":"OG002","value":"81","spread":null},{"groupId":"OG003","value":"75","spread":null},{"groupId":"OG004","value":"88","spread":null},{"groupId":"OG005","value":"80","spread":null},{"groupId":"OG006","value":"88","spread":null},{"groupId":"OG007","value":"81","spread":null},{"groupId":"OG008","value":"88","spread":null},{"groupId":"OG009","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":null},{"groupId":"OG001","value":"89","spread":null},{"groupId":"OG002","value":"88","spread":null},{"groupId":"OG003","value":"93","spread":null},{"groupId":"OG004","value":"96","spread":null},{"groupId":"OG005","value":"93","spread":null},{"groupId":"OG006","value":"97","spread":null},{"groupId":"OG007","value":"100","spread":null},{"groupId":"OG008","value":"96","spread":null},{"groupId":"OG009","value":"74","spread":null}]}]}]},{"type":"SECONDARY","title":"GMTs in Children Following a Fifth Dose of rMenB+OMV NZ Vaccine (at 4 Years of Age) Who Had Previously Received 3 Primary Doses and a Booster Dose of the Same Vaccine According to Different Schedules","description":"The GMTs, at one month after a 5th dose of rMenB+OMV NZ vaccine in children who had previously received 3 primary doses (at 2, 3, 4, or 2, 4, 6 months) and a booster dose (at 12, 18 or 24 months) of rMenB+OMV NZ vaccine according to different schedules, are compared with the GMTs of children who received first dose of rMenB+OMV NZ at 4 years of age.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"108","spread":null},{"groupId":"OG001","value":"115","spread":null},{"groupId":"OG002","value":"107","spread":null},{"groupId":"OG003","value":"173","spread":null},{"groupId":"OG004","value":"191","spread":null},{"groupId":"OG005","value":"212","spread":null},{"groupId":"OG006","value":"167","spread":null},{"groupId":"OG007","value":"146","spread":null},{"groupId":"OG008","value":"135","spread":null},{"groupId":"OG009","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"754","spread":null},{"groupId":"OG001","value":"1719","spread":null},{"groupId":"OG002","value":"933","spread":null},{"groupId":"OG003","value":"1959","spread":null},{"groupId":"OG004","value":"1387","spread":null},{"groupId":"OG005","value":"1954","spread":null},{"groupId":"OG006","value":"1711","spread":null},{"groupId":"OG007","value":"1239","spread":null},{"groupId":"OG008","value":"1280","spread":null},{"groupId":"OG009","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"28","spread":null},{"groupId":"OG003","value":"16","spread":null},{"groupId":"OG004","value":"21","spread":null},{"groupId":"OG005","value":"15","spread":null},{"groupId":"OG006","value":"26","spread":null},{"groupId":"OG007","value":"18","spread":null},{"groupId":"OG008","value":"27","spread":null},{"groupId":"OG009","value":"2.25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"19","spread":null},{"groupId":"OG002","value":"28","spread":null},{"groupId":"OG003","value":"32","spread":null},{"groupId":"OG004","value":"37","spread":null},{"groupId":"OG005","value":"33","spread":null},{"groupId":"OG006","value":"53","spread":null},{"groupId":"OG007","value":"58","spread":null},{"groupId":"OG008","value":"51","spread":null},{"groupId":"OG009","value":"20","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Ratios of GMTs in Subjects Following a Fifth Dose of rMenB+OMV NZ Vaccine (at 4 Years of Age), Who Had Previously Received 3 Primary Doses and a Booster Dose of the Same Vaccine According to Different Schedules","description":"The GMRs of GMTs (one month post booster/48 months persistence), one month after a 5th dose of rMenB+OMV NZ vaccine was given children, who had previously received 3 primary doses (at 2, 3, 4, or 2, 4, 6 months) and a booster dose (at 12, 18 or 24 months) of rMenB+OMV NZ vaccine according to different schedules is compared with the GMR (one month post 1 dose\\\\baseline) of children who received first dose of rMenB+OMV NZ at 4 years of age.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"72","spread":null},{"groupId":"OG002","value":"41","spread":null},{"groupId":"OG003","value":"77","spread":null},{"groupId":"OG004","value":"88","spread":null},{"groupId":"OG005","value":"46","spread":null},{"groupId":"OG006","value":"109","spread":null},{"groupId":"OG007","value":"63","spread":null},{"groupId":"OG008","value":"64","spread":null},{"groupId":"OG009","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"15","spread":null},{"groupId":"OG003","value":"30","spread":null},{"groupId":"OG004","value":"20","spread":null},{"groupId":"OG005","value":"18","spread":null},{"groupId":"OG006","value":"33","spread":null},{"groupId":"OG007","value":"20","spread":null},{"groupId":"OG008","value":"12","spread":null},{"groupId":"OG009","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"19","spread":null},{"groupId":"OG003","value":"8.93","spread":null},{"groupId":"OG004","value":"17","spread":null},{"groupId":"OG005","value":"13","spread":null},{"groupId":"OG006","value":"19","spread":null},{"groupId":"OG007","value":"14","spread":null},{"groupId":"OG008","value":"17","spread":null},{"groupId":"OG009","value":"2.25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.15","spread":null},{"groupId":"OG001","value":"4.46","spread":null},{"groupId":"OG002","value":"3.36","spread":null},{"groupId":"OG003","value":"3.49","spread":null},{"groupId":"OG004","value":"3.74","spread":null},{"groupId":"OG005","value":"4.21","spread":null},{"groupId":"OG006","value":"5.35","spread":null},{"groupId":"OG007","value":"3.86","spread":null},{"groupId":"OG008","value":"4.04","spread":null},{"groupId":"OG009","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentages of Subjects With Fourfold Increase in hSBA Titers After Receiving a Fifth Dose of rMenB+OMV NZ Vaccine (at 4 Years of Age), Who Had Previously Received 3 Primary Doses and a Booster Dose of the Same Vaccine According to Different Schedules","description":"The fourfold increase in hSBA titers, one month after a 5th dose of rMenB+OMV NZ vaccine was given to children, who had previously received 3 primary doses (at 2, 3, 4, or 2, 4, 6 months) and a booster dose (at 12,18 or 24 months) of rMenB+OMV NZ vaccine according to different schedules is compared with the response in children who received the first dose of rMenB+OMV NZ vaccine at 4 years of age.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"100","spread":null},{"groupId":"OG004","value":"96","spread":null},{"groupId":"OG005","value":"93","spread":null},{"groupId":"OG006","value":"97","spread":null},{"groupId":"OG007","value":"96","spread":null},{"groupId":"OG008","value":"96","spread":null},{"groupId":"OG009","value":"63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":null},{"groupId":"OG001","value":"94","spread":null},{"groupId":"OG002","value":"94","spread":null},{"groupId":"OG003","value":"100","spread":null},{"groupId":"OG004","value":"92","spread":null},{"groupId":"OG005","value":"100","spread":null},{"groupId":"OG006","value":"97","spread":null},{"groupId":"OG007","value":"96","spread":null},{"groupId":"OG008","value":"85","spread":null},{"groupId":"OG009","value":"86","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"61","spread":null},{"groupId":"OG002","value":"81","spread":null},{"groupId":"OG003","value":"69","spread":null},{"groupId":"OG004","value":"88","spread":null},{"groupId":"OG005","value":"73","spread":null},{"groupId":"OG006","value":"88","spread":null},{"groupId":"OG007","value":"72","spread":null},{"groupId":"OG008","value":"85","spread":null},{"groupId":"OG009","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"47","spread":null},{"groupId":"OG002","value":"31","spread":null},{"groupId":"OG003","value":"33","spread":null},{"groupId":"OG004","value":"39","spread":null},{"groupId":"OG005","value":"40","spread":null},{"groupId":"OG006","value":"49","spread":null},{"groupId":"OG007","value":"46","spread":null},{"groupId":"OG008","value":"32","spread":null},{"groupId":"OG009","value":"21","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentages of Subjects With hSBA Titers ≥1:5 and ≥1:8 Following a Third Dose of rMenB+OMV NZ Vaccine (at 4 Years of Age), Who Had Previously Received 2 Catch up Doses of the Same Vaccine According to Different Schedules","description":"The percentages of subjects with hSBA titers ≥1:5 and hSBA titers ≥1:8 at one month after a third dose of rMenB+OMV NZ vaccine was given to children, who had previously received 2 catch up doses (at 12,14 or 18,20 or 24,26 months) of the same vaccine according to different schedules, are reported.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":null},{"groupId":"OG001","value":"70","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"90","spread":null},{"groupId":"OG003","value":"77","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"60","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"90","spread":null},{"groupId":"OG003","value":"74","spread":null}]}]}]},{"type":"SECONDARY","title":"GMTs Following a Third Dose of rMenB+OMV NZ Vaccine in Children (at 4 Years of Age) Who Had Previously Received 2 Catch up Doses of the Same Vaccine According to Different Schedules","description":"The GMTs, one month following a third dose of rMenB+OMV NZ vaccine in 4 year old children who had previously received 2 catch up doses (at 12,14 or 18,20 or 24,26 months) of the same vaccine according to different schedules, are reported.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"154","spread":null},{"groupId":"OG001","value":"145","spread":null},{"groupId":"OG002","value":"211","spread":null},{"groupId":"OG003","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1575","spread":null},{"groupId":"OG001","value":"2381","spread":null},{"groupId":"OG002","value":"3604","spread":null},{"groupId":"OG003","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"47","spread":null},{"groupId":"OG003","value":"2.25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"74","spread":null},{"groupId":"OG002","value":"84","spread":null},{"groupId":"OG003","value":"20","spread":null}]}]}]},{"type":"SECONDARY","title":"GMRs of GMTs in Children Following a Third Dose of rMenB+OMV NZ Vaccine (at 4 Years of Age) Who Previously Received 2 Catch up Doses of the Same Vaccine According to Different Schedules.","description":"The GMRs of GMTs following a third dose of rMenB+OMV NZ vaccine (one month post 3rd dose/persistence at 48 months) in children, who had previously received 2 catch up doses (at 12, 14 or 18, 20 or 24, 26 months) of the same vaccine according to different schedules, are reported.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null},{"groupId":"OG001","value":"67","spread":null},{"groupId":"OG002","value":"133","spread":null},{"groupId":"OG003","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"51","spread":null},{"groupId":"OG002","value":"55","spread":null},{"groupId":"OG003","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"5.96","spread":null},{"groupId":"OG002","value":"38","spread":null},{"groupId":"OG003","value":"2.25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.24","spread":null},{"groupId":"OG001","value":"7.06","spread":null},{"groupId":"OG002","value":"7.35","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentages of Subjects With a 4-fold Increase in hSBA Titers Following a Third Dose of rMenB+OMV NZ Vaccine Given at 4 Years of Age to Children Who Previously Received 2 Catch up Doses of the Same Vaccine","description":"The percentage of subjects with a four-fold increase in hSBA titers following a third dose of rMenB+OMV NZ vaccine, who had previously received 2 catch up doses (at 12, 14 or 18, 20 or 24, 26 months) of rMenB+OMV NZ vaccine according to different schedules,are reported.\n\nFourfold increase is defined as- for subjects with a pre-vaccination titer \\<1:2 to a post-vaccination titer ≥1:8 and for subjects with a pre-vaccination titer ≥1:2 to a post-vaccination titer ≥ 4 fold pre-vaccination titer.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null},{"groupId":"OG001","value":"90","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"90","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"86","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"50","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"67","spread":null},{"groupId":"OG002","value":"56","spread":null},{"groupId":"OG003","value":"21","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentages of Subjects With hSBA ≥1:5 and ≥1:8 in Response of Two Catch up Doses of rMenB+OMV NZ Vaccine When Administered to Children at 4 Years of Age.","description":"The sufficiency of immune response is reported in terms of percentages of subjects with hSBA ≥1:5 and ≥1:8 in response of two catch up doses of rMenB+OMV NZ vaccine, administered two months apart, in children at 4 years of age.\n\nImmune response was considered sufficient if the lower limit of the two-sided 95% CI for the percentage of subjects achieving hSBA ≥ 1:5 at one month after the two-dose series was ≥ 70% for all three indicator (H44/76; 5/99 and NZ 98/254) strains.\n\nImmune sufficiency was not applicable for M10713 strain.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80","spread":null}]}]}]},{"type":"SECONDARY","title":"GMTs Following 2 Catch up Doses of rMenB+OMV NZ Vaccine at 4 Years of Age","description":"The GMTs in children who received two catch up doses of rMenB+OMV NZ vaccine at 48 and 50 months of age are reported.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"109","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"343","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null}]}]}]},{"type":"SECONDARY","title":"GMRs of GMTs Following 2 Catch up Doses of rMenB+OMV NZ Vaccine at 4 Years of Age","description":"The GMR of GMTs(one month post dose 2/baseline) in children following a two catch up dose of rMenB+OMV NZ at 48 and 50 months of age are reported.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"105","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"299","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.12","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentages of Subjects With 4-fold Increase in Serum Bactericidal Titers, Following 2 Catch up Doses of rMenB+OMV NZ Vaccine at 4 Years of Age","description":"The percentages of subjects with 4-fold increase in hSBA titers, one month following a two catch up dose of rMenB+OMV NZ at 4 years of age are reported.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Solicited Local and Systemic Adverse Events After Receiving a 5th Dose of rMenB+OMV NZ Vaccine (at 4 Years of Age)","description":"The safety and tolerability of the 5th dose rMenB+OMV NZ vaccine in children (at 4 years of age) who had previously received 3 primary doses (at 2, 3, 4, or 2, 4, 6 months) followed by a booster dose (at 12, 18 or 24 months) of rMenB+OMV NZ vaccine according to different schedules in the earlier studies is reported as number of subjects with solicited local and systemic adverse events.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"17","spread":null},{"groupId":"OG003","value":"16","spread":null},{"groupId":"OG004","value":"24","spread":null},{"groupId":"OG005","value":"17","spread":null},{"groupId":"OG006","value":"38","spread":null},{"groupId":"OG007","value":"28","spread":null},{"groupId":"OG008","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"6","spread":null},{"groupId":"OG004","value":"5","spread":null},{"groupId":"OG005","value":"2","spread":null},{"groupId":"OG006","value":"4","spread":null},{"groupId":"OG007","value":"6","spread":null},{"groupId":"OG008","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"13","spread":null},{"groupId":"OG003","value":"4","spread":null},{"groupId":"OG004","value":"14","spread":null},{"groupId":"OG005","value":"9","spread":null},{"groupId":"OG006","value":"24","spread":null},{"groupId":"OG007","value":"14","spread":null},{"groupId":"OG008","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"6","spread":null},{"groupId":"OG004","value":"4","spread":null},{"groupId":"OG005","value":"5","spread":null},{"groupId":"OG006","value":"10","spread":null},{"groupId":"OG007","value":"8","spread":null},{"groupId":"OG008","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"5","spread":null},{"groupId":"OG004","value":"6","spread":null},{"groupId":"OG005","value":"3","spread":null},{"groupId":"OG006","value":"5","spread":null},{"groupId":"OG007","value":"6","spread":null},{"groupId":"OG008","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"2","spread":null},{"groupId":"OG004","value":"7","spread":null},{"groupId":"OG005","value":"3","spread":null},{"groupId":"OG006","value":"10","spread":null},{"groupId":"OG007","value":"6","spread":null},{"groupId":"OG008","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"1","spread":null},{"groupId":"OG005","value":"1","spread":null},{"groupId":"OG006","value":"2","spread":null},{"groupId":"OG007","value":"0","spread":null},{"groupId":"OG008","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"2","spread":null},{"groupId":"OG004","value":"5","spread":null},{"groupId":"OG005","value":"2","spread":null},{"groupId":"OG006","value":"6","spread":null},{"groupId":"OG007","value":"7","spread":null},{"groupId":"OG008","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"2","spread":null},{"groupId":"OG005","value":"1","spread":null},{"groupId":"OG006","value":"2","spread":null},{"groupId":"OG007","value":"1","spread":null},{"groupId":"OG008","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"1","spread":null},{"groupId":"OG006","value":"1","spread":null},{"groupId":"OG007","value":"0","spread":null},{"groupId":"OG008","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"4","spread":null},{"groupId":"OG004","value":"5","spread":null},{"groupId":"OG005","value":"3","spread":null},{"groupId":"OG006","value":"7","spread":null},{"groupId":"OG007","value":"7","spread":null},{"groupId":"OG008","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"2","spread":null},{"groupId":"OG004","value":"3","spread":null},{"groupId":"OG005","value":"2","spread":null},{"groupId":"OG006","value":"7","spread":null},{"groupId":"OG007","value":"5","spread":null},{"groupId":"OG008","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"1","spread":null},{"groupId":"OG006","value":"1","spread":null},{"groupId":"OG007","value":"0","spread":null},{"groupId":"OG008","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"14","spread":null},{"groupId":"OG003","value":"18","spread":null},{"groupId":"OG004","value":"19","spread":null},{"groupId":"OG005","value":"13","spread":null},{"groupId":"OG006","value":"36","spread":null},{"groupId":"OG007","value":"27","spread":null},{"groupId":"OG008","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"12","spread":null},{"groupId":"OG004","value":"7","spread":null},{"groupId":"OG005","value":"8","spread":null},{"groupId":"OG006","value":"20","spread":null},{"groupId":"OG007","value":"11","spread":null},{"groupId":"OG008","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"5","spread":null},{"groupId":"OG004","value":"2","spread":null},{"groupId":"OG005","value":"4","spread":null},{"groupId":"OG006","value":"7","spread":null},{"groupId":"OG007","value":"5","spread":null},{"groupId":"OG008","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"9","spread":null},{"groupId":"OG004","value":"8","spread":null},{"groupId":"OG005","value":"5","spread":null},{"groupId":"OG006","value":"11","spread":null},{"groupId":"OG007","value":"8","spread":null},{"groupId":"OG008","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"3","spread":null},{"groupId":"OG004","value":"2","spread":null},{"groupId":"OG005","value":"3","spread":null},{"groupId":"OG006","value":"7","spread":null},{"groupId":"OG007","value":"5","spread":null},{"groupId":"OG008","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"11","spread":null},{"groupId":"OG003","value":"14","spread":null},{"groupId":"OG004","value":"13","spread":null},{"groupId":"OG005","value":"8","spread":null},{"groupId":"OG006","value":"23","spread":null},{"groupId":"OG007","value":"20","spread":null},{"groupId":"OG008","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"2","spread":null},{"groupId":"OG004","value":"4","spread":null},{"groupId":"OG005","value":"2","spread":null},{"groupId":"OG006","value":"6","spread":null},{"groupId":"OG007","value":"4","spread":null},{"groupId":"OG008","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"1","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"5","spread":null},{"groupId":"OG007","value":"3","spread":null},{"groupId":"OG008","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"2","spread":null},{"groupId":"OG004","value":"1","spread":null},{"groupId":"OG005","value":"1","spread":null},{"groupId":"OG006","value":"5","spread":null},{"groupId":"OG007","value":"4","spread":null},{"groupId":"OG008","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"2","spread":null},{"groupId":"OG005","value":"1","spread":null},{"groupId":"OG006","value":"7","spread":null},{"groupId":"OG007","value":"1","spread":null},{"groupId":"OG008","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"3","spread":null},{"groupId":"OG004","value":"3","spread":null},{"groupId":"OG005","value":"1","spread":null},{"groupId":"OG006","value":"10","spread":null},{"groupId":"OG007","value":"4","spread":null},{"groupId":"OG008","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Solicited Local and Systemic Adverse Events After Receiving a 3rd Dose of rMenB+OMV NZ Vaccine (at 4 Years of Age)","description":"The safety and tolerability of the 3rd dose rMenB+OMV NZ vaccine in children (at 4 years of age) who had previously received 2 catch up doses (at 12, 14 or 18, 20 or 24, 26 months) of rMenB+OMV NZ vaccine according to different schedules is reported as number of subjects with solicited local and systemic adverse events.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Solicited Local and Systemic Adverse Events After Receiving a 2 Catch up Doses of rMenB+OMV NZ Vaccine at 4 Years of Age","description":"The safety and tolerability of rMenB+OMV NZ vaccine in 4 year old children who received 2 catch up doses of rMenB+OMV NZ vaccine at 48 and 50 months, is reported as number of subjects with solicited local\\* and systemic adverse events.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"186","spread":null},{"groupId":"OG001","value":"161","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77","spread":null},{"groupId":"OG001","value":"66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"137","spread":null},{"groupId":"OG001","value":"108","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Unsolicited AEs After Receiving a 5th Dose of rMenB+OMV NZ Vaccine (at 4 Years of Age)","description":"The safety and tolerability of the 5th dose rMenB+OMV NZ vaccine in children (at 4 years of age) who had previously received 3 primary doses (at 2, 3, 4,or 2, 4, 6 months) followed by a booster dose (at 12, 18 or 24 months) of rMenB+OMV NZ vaccine according to different schedules in the earlier studies is reported as number of subjects with unsolicited AEs, Serious Adverse Events (SAE), AEs leading to premature withdrawal.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"7","spread":null},{"groupId":"OG004","value":"7","spread":null},{"groupId":"OG005","value":"3","spread":null},{"groupId":"OG006","value":"11","spread":null},{"groupId":"OG007","value":"11","spread":null},{"groupId":"OG008","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null},{"groupId":"OG008","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null},{"groupId":"OG008","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Unsolicited AEs After Receiving a 3rd Dose of rMenB+OMV NZ Vaccine (at 4 Years of Age)","description":"The safety and tolerability of the 3rd dose rMenB+OMV NZ vaccine in children (at 4 years of age) who had previously received 2 catch up doses (at 12, 14 or 18, 20 or 24, 26 months) of rMenB+OMV NZ vaccine according to different schedules is reported as number of subjects with Unsolicited AEs, Serious Adverse Events (SAEs), AEs leading to premature withdrawal.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Unsolicited AEs After Any Vaccination.","description":"The safety and tolerability of the 3rd dose rMenB+OMV NZ vaccine in children (at 4 years of age) who had previously received 2 catch up doses (at 12, 14 or 18, 20 or 24, 26 months) of rMenB+OMV NZ vaccine according to different schedules is reported as number of subjects with unsolicited AEs, Serious Adverse Events (SAEs), AEs leading to premature withdrawal.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"105","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":30},"commonTop":["INJECTION SITE PAIN","INJECTION SITE ERYTHEMA","INJECTION SITE INDURATION","IRRITABILITY","SOMNOLENCE"]}}}